Dose-Escalation Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2

Publication date: Feb 28, 2024

This is an open-label phase 1/2, dose-escalation study. Participants will receive a single intramuscular (IM) dose of IMNN-101 on Day 0 in the deltoid muscle and will be followed through 12 months post-vaccination (through Study Day 365).

Concepts Keywords
Biochemistry Day
Liver Days
Malignant Dose
Vaccinated Group


Type Source Name
disease VO dose
disease VO vaccinated
disease VO vaccination
disease IDO process
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease VO immunization
disease VO time
disease IDO site
disease MESH HIV infection
disease MESH Hepatitis C
pathway KEGG Hepatitis C
drug DRUGBANK Hepatitis B Vaccine (Recombinant)
disease VO Hepatitis B surface antigen
disease VO device
disease VO Hormone
drug DRUGBANK Chorionic Gonadotropin (Human)
disease IDO history
disease VO COVID-19 vaccine
disease VO vaccine
disease MESH nasal obstruction
disease VO nose
disease MESH sore throat
disease IDO blood
disease MESH myocarditis
disease MESH pericarditis
disease MESH allergic reactions
disease MESH anaphylaxis
disease MESH urticaria
disease MESH eczema
disease MESH angioneurotic edema
disease MESH CNS disease
disease MESH convulsions
disease MESH epilepsy
disease MESH encephalopathy
disease MESH mental illness
disease MESH kidney diseases
disease MESH hypertension
disease MESH diabetic complications
disease MESH tumors
disease MESH bacterial infections
disease MESH chronic disease
disease MESH lymphoma
disease MESH leukemia
disease MESH autoimmune diseases
drug DRUGBANK Ethanol
disease MESH drug abuse
disease IDO quality

Original Article

(Visited 1 times, 1 visits today)